NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $5.70 +0.43 (+8.16%) (As of 09:32 AM ET) Add Compare Share Share Today's Range$5.36▼$5.7050-Day Range$3.92▼$9.1052-Week Range$1.96▼$9.97Volume141,356 shsAverage Volume1.80 million shsMarket Capitalization$678.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Humacyte alerts: Email Address Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside48.1% Upside$8.00 Price TargetShort InterestBearish5.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 13 Articles This WeekInsider TradingSelling Shares$12.46 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.95) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector415th out of 879 stocksBiological Products, Except Diagnostic Industry56th out of 150 stocks 3.4 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 2 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.65% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Humacyte has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 2.0 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Humacyte this week, compared to 3 articles on an average week.Search InterestOnly 15 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -66% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -77% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have sold 3,276.83% more of their company's stock than they have bought. Specifically, they have bought $369,107.00 in company stock and sold $12,464,121.00 in company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.95) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 41.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Humacyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesJune 15, 2024 | insidertrades.comHumacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan Sells 271,518 SharesJuly 4, 2024 | americanbankingnews.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest UpdateJuly 8, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 3, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Shares Gap Up to $4.80July 3, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives "Overweight" Rating from Cantor FitzgeraldJuly 2, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by BenchmarkJuly 1, 2024 | globenewswire.comHumacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)May 30, 2024 | globenewswire.comHumacyte to Present at the Jefferies Global Healthcare ConferenceJuly 8, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 21, 2024 | finance.yahoo.comThis Humacyte Insider Increased Their Holding By 91% Last YearMay 14, 2024 | msn.comHumacyte extends gains as FDA reviews blood vessel productMay 13, 2024 | markets.businessinsider.comBenchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)May 13, 2024 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comHumacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 13, 2024 | finance.yahoo.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 13, 2024 | globenewswire.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 11, 2024 | finance.yahoo.comQ1 2024 Humacyte Inc Earnings CallMay 10, 2024 | benzinga.comPeering Into Humacyte's Recent Short InterestSee More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees183Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+51.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-306.81% Return on Assets-69.64% Debt Debt-to-Equity Ratio0.61 Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$1.57 million Price / Sales399.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book40.54Miscellaneous Outstanding Shares119,080,000Free Float91,576,000Market Cap$627.55 million OptionableOptionable Beta1.51 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 61)Ph.D., Founder, President, CEO & Director Comp: $899.25kMr. Dale A. Sander (Age 64)CFO, Chief Corporate Development Officer & Treasurer Comp: $704.33kDr. Heather Ledbetter Prichard Ph.D. (Age 46)Chief Operating Officer Comp: $647.78kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 52)Chief Commercial Officer Dr. Shamik J. Parikh M.D. (Age 51)Chief Medical Officer Comp: $514.72kMr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 58)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsDasekeNASDAQ:DSKEEvolv TechnologiesNASDAQ:EVLVBARKNYSE:BARKSystem1NYSE:SSTBeachbodyNYSE:BODYView All CompetitorsInsiders & InstitutionsBrady W DouganSold 271,518 sharesTotal: $1.98 M ($7.30/share)Laura E NiklasonSold 358,630 sharesTotal: $2.54 M ($7.08/share)Brady W DouganBought 2,362 shares on 6/4/2024Total: $14,998.70 ($6.35/share)Laura E NiklasonBought 2,050 shares on 6/3/2024Total: $15,108.50 ($7.37/share)Laura E NiklasonSold 809,786 sharesTotal: $6.41 M ($7.91/share)View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $2.84 on January 1st, 2024. Since then, HUMA shares have increased by 90.1% and is now trading at $5.40. View the best growth stocks for 2024 here. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) announced its quarterly earnings data on Friday, May, 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
